Key points from article :
A new partnership between Bio-ReCell and Swedish company AcouSort promises to accelerate the development of automated systems for isolating stem and immune cells from fat tissue—an essential step in many advanced cell therapies. The two firms have signed a Letter of Intent to integrate AcouSort’s acoustofluidic separation technology with Bio-ReCell’s Revive™ SVF device, which is used to process adipose tissue.
The collaboration builds on a successful pilot trial at AcouSort’s lab in Lund, where the acoustic separation method was tested on cell samples prepared by Bio-ReCell. The next stage will focus on refining and adapting the technology for streamlined and efficient use in clinical and research settings.
According to Dr. Luka Fajs, CEO of Bio-ReCell, the joint effort highlights the power of strategic collaboration in pushing the frontiers of cell therapy. AcouSort’s CEO Torsten Freltoft echoed this sentiment, emphasizing the company’s commitment to innovation through partnerships. By combining their respective expertise, the two companies aim to improve cell processing and help drive the future of regenerative medicine.
